- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Multiple Endocrine Neoplasia Type 2B
Total 58891 results
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
-
University of CalgaryRecruiting
-
Novartis PharmaceuticalsCompletedMayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGoSecondary Progressive Multiple SclerosisAustralia
-
SanofiActive, not recruitingSecondary Progressive Multiple SclerosisUnited States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
-
University of NottinghamNottingham University Hospitals NHS TrustCompletedSecondary Progressive Multiple SclerosisUnited Kingdom
-
University College, LondonUniversity of Leeds; University of Sheffield; Medical Research Council; Queen Mary... and other collaboratorsCompletedSecondary Progressive Multiple SclerosisUnited Kingdom
-
Isfahan University of Medical SciencesCompletedSecondary Progressive Multiple SclerosisIran, Islamic Republic of
-
BiogenTerminatedSecondary Progressive Multiple SclerosisUnited States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
-
Eli Lilly and CompanyBioMS Technology Corp.TerminatedSecondary Progressive Multiple SclerosisCanada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
-
Eli Lilly and CompanyBioMS Technology Corp.CompletedSecondary Progressive Multiple SclerosisCanada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
-
Wyeth is now a wholly owned subsidiary of PfizerTerminatedSecondary Progressive Multiple SclerosisGermany
-
AbbVieTerminatedExocrine Pancreatic Insufficiency (EPI)United States
-
Innate ImmunotherapeuticsSyneos HealthCompletedSecondary Progressive Multiple SclerosisNew Zealand, Australia
-
BiogenTerminatedMultiple Sclerosis, Secondary ProgressiveUnited States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
-
BiogenWithdrawn
-
University College London HospitalsCompletedSecondary Progressive Multiple SclerosisUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)TerminatedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
Tehran University of Medical SciencesCompletedMultiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple SclerosisIran, Islamic Republic of
-
University Hospital, MontpellierTerminatedType 1 Diabetes | Basal-bolus Multiple-dily Insulin Injections | Insulin Pump (CSII)France
-
Novartis PharmaceuticalsActive, not recruitingActive Secondary Progressive Multiple SclerosisItaly
-
Novartis PharmaceuticalsTerminatedSecondary Progressive Multiple Sclerosis With Inflammatory Disease ActivitySwitzerland
-
Memorial Sloan Kettering Cancer CenterHealthTree FoundationRecruitingMultiple Myeloma, SmolderingUnited States
-
Regeneron PharmaceuticalsRecruiting
-
Omar Nadeem, MDJanssen, LPRecruitingMultiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Icahn School of Medicine at Mount SinaiPharmacyclics LLC.TerminatedHigh Risk Smoldering Multiple MyelomaUnited States
-
University of ArkansasMillennium Pharmaceuticals, Inc.CompletedAsymptomatic Multiple MyelomaUnited States
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
US Oncology ResearchKaryopharm Therapeutics IncRecruitingMultiple Myeloma | Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Kahler Disease | Myeloma, Plasma Cell | MyelomatosisUnited States
-
University of Illinois at ChicagoCompletedMultiple Myeloma, Relapsed | Multiple Myeloma, Refractory to Standard TreatmentUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
Shanghai Theorion Pharmaceutical Co Ltd.Shanghai Institute of Materia Medica, Chinese Academy of SciencesUnknownRefractory Multiple Myeloma | Recurrent Multiple MyelomaChina
-
Masonic Cancer Center, University of MinnesotaTerminatedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Germ Cell TumorUnited States
-
Medical College and Hospital KolkataSir Ganga Ram HospitalCompletedPancreatic Endocrine Neoplasms
-
Kyverna TherapeuticsNot yet recruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
-
University of UtahCompletedMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple SclerosisUnited States
-
Fondazione Policlinico Universitario Campus Bio-MedicoCompleted
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States